Long-term bone treatment for steroid-related osteoporosis
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study is checking the long-term effects of two osteoporosis treatments (romosozumab and denosumab) in people whose bone thinning was caused by steroids. If you have been in the study for 4 years already, it looks at how well continuing denosumab works over 6 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier part of this study and continued taking denosumab injections every 6 months after month 48.
- You must be willing to have a bone density scan at the 6-year mark.
- You cannot be taking any other osteoporosis medications besides denosumab.
- You must not plan to stop or reduce your prednisolone (a steroid) treatment after month 48.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
This study tests whether taking two osteoporosis medicines together (romosozumab and denosumab) can help prevent more broken bones in women after menopause who have already had several fractures. It may be a good option if you have weak bones and want to lower your risk of future breaks.
This study compares two treatments for osteoporosis in postmenopausal women: a sequence of romosozumab followed by denosumab versus zoledronic acid alone. The goal is to see which approach better improves bone density in the hip. Participants will receive either the combination or the single drug for a period, and their progress will be monitored.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
Hear when a new Glucocorticoid-Associated Osteopenia and Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.